Medicare AdvantageCoverageMedium impact
MA06.036, Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Independence Blue Cross·Urology, Oncology, Family Medicine +1 more·Medical Policy
Effective date
Jan 27, 2025
We identified it
Jun 19, 2026
Summary
A new Medicare Advantage policy MA06.036 has been established covering protein biomarkers for prostate cancer diagnosis and risk assessment. This policy will define coverage criteria and billing requirements for protein biomarker testing used in prostate cancer evaluation.
Action Required
By January 27, 2025: Billing team must review the full policy details at the provided URL to understand coverage criteria for protein biomarker testing in prostate cancer diagnosis. Update billing procedures and prior authorization requirements as specified in the complete policy document. Notify providers of any documentation requirements for prostate cancer biomarker testing.